JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies

JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies

Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, arising from immature lymphocytes that show uncontrolled proliferation and arrested differentiation. Genomic alterations affecting Janus kinase 2 (JAK2) correlate with some of the poorest outcomes within the Philadelphia-like su...

Full description

Bibliographic Details
Main Authors: Charlotte EJ. Downes, Barbara J. McClure, Daniel P. McDougal, Susan L. Heatley, John B. Bruning, Daniel Thomas, David T. Yeung, Deborah L. White
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
leukemia
Janus kinases
kinase inhibitor
JAK2
targeted therapy
acute lymphoblastic leukemia
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2022.942053/full

Internet

https://www.frontiersin.org/articles/10.3389/fcell.2022.942053/full

Similar Items